Turk Kardiyol Dern Ars. 2021; 49(4): 286-292 | DOI: 10.5543/tkda.2021.87750
Comparison of hypertension prevalence and the use of renin-angiotensin-aldosterone system blockers in hospitalized patients with COVID-19 and non-COVID-19 viral pneumonia
, Ceyda Erel Kırışoğlu2
, Mehmet Erkan Ekicibaşı3
, Aleks Değirmencioğlu4
, Ashok Paudel3
, Gökçe Akan5
, Fatmahan Atalar6
, Nevin Sarıgüzel7
, Burak Pamukçu81
Department of Cardiology, Acıbadem Mehmet Ali Aydınlar University School of Medicine, İstanbul, Turkey2
Department of Chest Diseases and Tuberculosis, Faculty of Medicine, Acibadem Mehmet Ali Aydinlar University, Istanbul, Turkey3
Department of Cardiology, Acibadem Altunizade Hospital, Acibadem Healthcare Group, Istanbul, Turkey4
Department of Cardiology, Acibadem Maslak Hospital, Acibadem Healthcare Group, Istanbul, Turkey5
Muhimbili University of Health and Allied Sciences, Department of Biochemistry, MUHAS Genetics Laboratory, Dar es Salaam, Tanzania6
Department of Family Health, Child Health Institute, Istanbul University, Istanbul, Turkey7
Department of Infectious Diseases, Acibadem Kadikoy & Kozyatagi Hospitals, Acibadem Healthcare Group, Istanbul, Turkey8
Department of First and Emergency Aid, Vocational School of Health Services, Acibadem Mehmet Ali Aydinlar University, Istanbul, Turkey
OBJECTIVE To compare the prevalence of hypertension and pre-existing use of renin-angiotensin-aldosterone system blockers in patients with coronavirus disease (COVID-19) and non-COVID-19 viral pneumonias.
METHODS Real-time polymerase chain reaction confirmed COVID-19 and non-COVID-19 pneumonia patients were retrospectively analyzed. The presence of hypertension, coronary artery disease (CAD), and pre-existing use of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) were compared between the groups.
RESULTS A total of 103 COVID-19 and 91 non-COVID-19 hospitalized viral pneumonia patients were enrolled. Hypertension and CAD were more common in patients with non-COVID-19 viral pneumonia than in patients with COVID-19 (39.6% vs 22.3%, respectively, p=0.012 and 24.2% vs 4.9%, respectively, p<0.001). In our study, 2.9% and 6.8% of patients with COVID-19 were on ACEIs and ARBs, respectively, whereas 13.2% and 19.8% of patients with non-COVID-19 viral pneumonia were on ACEIs and ARBs, respectively (p=0.009 and p=0.013). Neutrophil-to-lymphocyte ratio (p<0.001) was prominent in patients with non-COVID-19 viral pneumonia compared with patients with COVID-19.
CONCLUSION Our study results indicate that hypertension and CAD are more common among patients with non-COVID-19 viral pneumonia than patients with COVID-19. The prevalence of ACEIs and ARBs use was not higher in patients with COVID-19. Our results support that the use of ACEIs and ARBs do not play a specific role in patients with COVID-19.
COVID-19, viral pneumonia, hypertension, angiotensin-converting enzyme inhibitors, angiotensin II type 2 receptor blockers.
How to cite this article
Selçuk Görmez, Ceyda Erel Kırışoğlu, Mehmet Erkan Ekicibaşı, Aleks Değirmencioğlu, Ashok Paudel, Gökçe Akan, Fatmahan Atalar, Nevin Sarıgüzel, Burak Pamukçu. Comparison of hypertension prevalence and the use of renin-angiotensin-aldosterone system blockers in hospitalized patients with COVID-19 and non-COVID-19 viral pneumonia. Turk Kardiyol Dern Ars. 2021; 49(4): 286-292
Corresponding Author: Burak Pamukçu, Türkiye